- Home
- IDN vs FBIO Comparison
IDN vs FBIO Comparison
Compare IDN & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDN
- FBIO
- Stock Information
- Founded
- IDN 1994
- FBIO 2006
- Country
- IDN United States
- FBIO United States
- Employees
- IDN N/A
- FBIO N/A
- Industry
- IDN Computer Software: Prepackaged Software
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- IDN Technology
- FBIO Health Care
- Exchange
- IDN Nasdaq
- FBIO Nasdaq
- Market Cap
- IDN 46.8M
- FBIO 49.1M
- IPO Year
- IDN 1999
- FBIO N/A
- Fundamental
- Price
- IDN $2.83
- FBIO $1.69
- Analyst Decision
- IDN Buy
- FBIO Strong Buy
- Analyst Count
- IDN 2
- FBIO 3
- Target Price
- IDN $3.00
- FBIO $21.00
- AVG Volume (30 Days)
- IDN 47.0K
- FBIO 144.5K
- Earning Date
- IDN 05-13-2025
- FBIO 05-19-2025
- Dividend Yield
- IDN N/A
- FBIO N/A
- EPS Growth
- IDN N/A
- FBIO N/A
- EPS
- IDN N/A
- FBIO N/A
- Revenue
- IDN $19,997,000.00
- FBIO $57,675,000.00
- Revenue This Year
- IDN $7.60
- FBIO $63.20
- Revenue Next Year
- IDN $10.02
- FBIO $66.70
- P/E Ratio
- IDN N/A
- FBIO N/A
- Revenue Growth
- IDN 5.77
- FBIO N/A
- 52 Week Low
- IDN $1.92
- FBIO $1.33
- 52 Week High
- IDN $4.46
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- IDN 61.62
- FBIO 52.97
- Support Level
- IDN $2.47
- FBIO $1.67
- Resistance Level
- IDN $2.87
- FBIO $1.84
- Average True Range (ATR)
- IDN 0.17
- FBIO 0.09
- MACD
- IDN 0.03
- FBIO 0.01
- Stochastic Oscillator
- IDN 92.86
- FBIO 58.54
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.